



Europäisches Patentamt
European Patent Office
Office européen des brevets

Publication number:

0 171 372
A1

EUROPEAN PATENT APPLICATION

Application number: 85850199.2

Int. Cl.: C 07 D 513/14, A 61 K 31/54

Date of filing: 06.08.85

Priority: 13.06.84 SE 8403179

Applicant: Aktiebolaget Hässle, Kärnagatan 5,
S-431 83 Mölndal (SE)

Date of publication of application: 12.02.86
Bulletin 86/7


Inventor: Brändström, Arne Elof, And.
Mattssongata 13 B, S-415 06 Göteborg (SE)
Inventor: Lindberg, Per Lennart, Knapehall 84,
S-436 00 Askim (SE)
Inventor: Wallmark, Björn, Rada Portar 97,
S-435 00 Mölmycke (SE)

Designated Contracting States: AT BE CH DE FR GB IT
LI LU NL SE

Representative: Hjertman, Ivan T. et al, AB ASTRA
Patent and Trade Mark Department, S-151 85 Södertälje
(SE)

Sulphenamides, processes for their preparation and their use in the manufacture of pharmaceutical preparations.

Novel compounds of the formula IIIa



wherein R^{1a} , R^{2a} , R^{3a} and R^{4a} are the same or different and are hydrogen, an alkyl, alkoxy optionally completely or predominantly substituted by fluorine or chlorine, halogen, $-CN$, $-CF_3$, $-NO_2$, $-COR$, $-COOR$, aryl, aryloxy or arylalkoxy group, or adjacent groups R^{1a} , R^{2a} , R^{3a} and R^{4a} together with the adjacent carbon atoms in the benzimidazole ring form a 5-, 6- or 7-membered monocyclic ring or a 9-, 10- or 11-membered bicyclic ring, which rings may be saturated or unsaturated and may contain 0-3 heteroatoms selected from N and

O and which rings may be optionally substituted with 1-4 substituents selected from alkyl groups with 1-3 carbon atoms, halogen preferably F or Cl, alkylene radicals containing 4-5 carbon atoms giving spiro compounds, or two or four of these substituents together form one or two oxy groups

$(-C-)$, whereby if R^{1a} , R^{2a} , R^{3a} and R^{4a} together with the adjacent carbon atoms in the benzimidazole ring form two rings they may be condensed with each other, R^{5a} is hydrogen or an alkyl group, R^{6a} is hydrogen or an alkyl group or R^{6a} and R^{7a} are joined together to form an alkylene chain, R^{7a} is hydrogen, an alkyl, alkoxy, alkenyloxy or alkynyloxy group, R^{8a} is hydrogen or an alkyl group, or R^{6a} and R^{7a} , or R^{7a} and R^{8a} together with the adjacent carbon atoms in the pyridinium ring form a ring wherein the part constituted by R^{6a} and R^{7a} or R^{7a} and R^{8a} is $-CH=CH-CH=CH-$, $-O-(CH_2)_p-$, $-CH_2(CH_2)_p-$, $-O-CH=CH-$, $-NH-CH=CH-$, $-N-CH=$
 CH_2

$CH-$, or $-S-(CH_2)_p-$, wherein p is 2, 3 or 4 and the O, S and N atoms always are attached to position 3 in the compound IIIa, R is an alkyl, cycloalkyl, aryl or arylalkyl group, and X^- is a pharmaceutically acceptable anion, process for preparation thereof, pharmaceutical compositions containing such compounds and their use in medicine.

TITLE MODIFIED

0171372


New sulphenamides, processes for their preparation and their use in affecting gastric acid secretion and providing gastrointestinal cytoprotective effect.

Field of the invention

The present invention is related to new sulphenamide salts having valuable therapeutic properties especially in affecting gastric acid secretion and providing gastrointestinal cytoprotective effect in mammals, including man, as well as processes for the preparation of the new compounds, pharmaceutical compositions comprising them and a method of affecting gastric acid secretion and providing gastrointestinal cytoprotective effect when using them.

Background of the invention

From e.g. EP-A1-0 005 129 sulfoxides of the benzimidazole type with the general formula I



in which R¹ and R² are the same or different and are hydrogen, alkyl, halogen, methoxycarbonyl, ethoxycarbonyl, alkoxy, or alkanoyl in any position, R⁶ is hydrogen, methyl or ethyl, R³, R⁴ and R⁵ are the same or different and are each hydrogen, methyl, methoxy, ethoxy, methoxyethoxy or ethoxyethoxy, whereby R³, R⁴ and R⁵ are not all hydrogen, and whereby when two of R³, R⁴ and R⁵ are hydrogen, the third of R³, R⁴ and R⁵ is not methyl, as well as pharmaceutically acceptable salts thereof are known. The compounds with the general formula I can be used in the treatment of gastrointestinal diseases.

The compounds are known to inhibit gastric acid secretion and have also a gastric cytoprotective effect. Because of their antisecretory effect they may be used in the treatment of peptic ulcer.

5

10

15




25

30

Compounds of the invention are compounds of the general formula IIIa

0171372



- wherein R^{1a} , R^{2a} , R^{3a} and R^{4a} are the same or different and are hydrogen
 an alkyl, alkoxy, optionally completely or predominantly substituted
 by fluorine or chlorine, halogen, $-\text{CN}$, $-\text{CF}_3$, $-\text{NO}_2$, $-\text{COR}$, $-\text{COOR}$, aryl,
 aryloxy or arylalkoxy group, or adjacent groups R^{1a} , R^{2a} , R^{3a} and R^{4a}
 5 together with the adjacent carbon atoms in the benzimidazole ring form
 a 5-, 6- or 7-membered monocyclic ring or a 9-, 10- or 11- membered
 bicyclic ring, which rings may be saturated or unsaturated and may
 contain 0-3 hetero atoms selected from N and O and which rings may be
 optionally substituted with 1-4 substituents selected from alkyl groups
 10 with 1-3 carbon atoms, halogen preferably F or Cl, alkylene radicals
 containing 4-5 carbon atoms giving spiro compounds, or two or four of
 these substituents together form one or two oxy groups ($-\text{C}-$), whereby

$$\begin{array}{c} \parallel \\ \text{O} \end{array}$$

 if R^{1a} , R^{2a} , R^{3a} and R^{4a} together with the adjacent carbon atoms in
 15 the benzimidazole ring form two rings they may be condensed with each
 other, R^{5a} is hydrogen or an alkyl group, R^{6a} is hydrogen or an alkyl
 group or R^{5a} and R^{6a} are joined together to form an alkenylene chain,
 R^{7a} is hydrogen, an alkyl, alkoxy, alkenyloxy or alkynyloxy group, R^{8a}
 is hydrogen or an alkyl group, or R^{6a} and R^{7a} , or R^{7a} and R^{8a} together
 20 with the adjacent carbon atoms in the pyridinium ring form a ring where-
 in the part constituted by R^{6a} and R^{7a} or R^{7a} and R^{8a} , is $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$,
 $-\text{O}-(\text{CH}_2)_p-$, $-\text{CH}_2(\text{CH}_2)_p-\text{O}-\text{CH}=\text{CH}-$, $-\text{NH}-\text{CH}=\text{CH}-$, $-\text{N}-\text{CH}=\text{CH}-$, or $-\text{S}-(\text{CH}_2)_p-$,

$$\begin{array}{c} \text{CH}_3 \\ | \\ \text{CH} \end{array}$$

 wherein p is 2, 3 or 4 and the O, S and N atoms always are attached
 25 to position 3 in the compound IIIa, R is an alkyl, cycloalkyl, aryl
 or arylalkyl group, and X^- is a pharmaceutically acceptable anion e.g.
 Cl^- , Br^- , I^- , BF_4^- , PF_6^- or AuCl_4^- .

R^{1a} , R^{2a} , R^{3a} , R^{4a} , R^{5a} , R^{6a} , R^{7a} , R^{8a} and R representing an alkyl group is preferably a lower alkyl group having 1-7 carbon atoms, especially preferred 1-4 carbon atoms, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl.

5

R^{1a} , R^{2a} , R^{3a} , R^{4a} and R^{7a} representing an alkoxy group is preferably a lower alkoxy group having 1-7 carbon atoms, especially preferred 1-3 carbon atoms e.g. methoxy, ethoxy, n-propoxy or isopropoxy.

10

R^{1a} , R^{2a} , R^{3a} and R^{4a} representing a halogen is chloro, bromo, fluoro or iodo.

R^{1a} , R^{2a} , R^{3a} , R^{4a} and R representing an aryl has preferably up to 10 carbon atoms, especially preferred up to 6 carbon atoms e.g. phenyl.

15

R^{1a} , R^{2a} , R^{3a} and R^{4a} representing an aryloxy group has preferably up to 10 carbon atoms, especially preferred up to 6 carbon atoms, e.g. phenoxy.

20

R^{1a} , R^{2a} , R^{3a} and R^{4a} representing an arylalkoxy group and R representing an arylalkyl group, have preferably up to 10 carbon atoms in the aryl group and 1-7 carbon atoms in the alkoxy group or the alkyl group, respectively, especially preferred is a group having up to 6 carbon atoms in the aryl group and 1-3 carbon atoms in the alkoxy group or the alkyl group, respectively, e.g. phenylmethoxy, and phenylmethyl.

25

R^{5a} and R^{6a} representing an alkenylene chain having 3 carbon atoms, thus forming a quinoline ring is especially preferred.

30

R^{7a} representing an alkenyloxy or alkynyloxy group has preferably 2-5 carbon atoms, especially preferred 3 carbon atoms.

R representing a cycloalkyl group has preferably 3-10 carbon atoms, especially preferred 3 carbon atoms.

35


A preferred group of compounds with the general formula IIIa are those wherein at least two of R^{1a} , R^{2a} , R^{3a} and R^{4a} are hydrogen and one or

two of the other is a methyl group, R^{5a} is hydrogen, at least one of R^{6a} and R^{8a} is a methyl group and R^{7a} is hydrogen or a methoxy group.

Especially preferred according to the invention is the isomeric mixture
 5 of 2,4-dimethyl-3,9-dimethoxy-5H-pyrido[1',2':4,5][1,2,4]thiadiazino-
 [2,3-a]benzimidazol-13-ium tetrafluoroborate and 2,4-dimethyl-3,10-
 dimethoxy-5H-pyrido[1',2':4,5][1,2,4]thiadiazino[2,3-a]benzimidazol-
 13-ium tetrafluoroborate.

10 The new compounds with the general formula IIIa according to this inven-
 tion are potent enzyme inhibitors, primarily inhibitors of the enzyme
 H^+, K^+ -ATPase. In addition, the new compounds exhibit a gastrointestinal
 cytoprotective effect. In the form of a suitable pharmaceutical composi-
 tion, the new compounds are therapeutically useful, primarily in the
 15 treatment of gastric disorders, such as gastrointestinal inflammatory
 diseases, including e.g. gastritis, gastric and duodenal ulcer. They
 may also be used as gastrointestinal cytoprotecting agents.

Compounds of the general formula IIIa above may be prepared according
 20 to the following method



The transformation reaction probably goes via the sulphenic acid IIa, which may also be an in vivo inhibitor, when a sulfoxide with the general formula Ia has been administered. However, the sulphenic acid is probably not an isolable compound. The transformation from the
5 sulfoxide to the sulphenamide goes via two different pathways, namely
a) one acid catalyzed and
b) one non-acid catalyzed pathway. Both pathways, however, give the same sulphenamide, IIIa.

10 Especially preferred acids for preparation of the compounds with the general formula IIIa are HPF_6 , HBF_4 , HAuCl_4 and HCl .

The compounds with the general formula Ia, wherein R^{5a} and R^{6a} together
15 form an alkenylene chain are new compounds, which form a part of the invention.

The compounds with the general formula IIa are new compounds, which form a part of the invention.

20

Method a)

0.005 mole of a sulfoxide with the general formula Ia is dissolved in 50 ml of 0.2 M HCl in CH_3OH (1 ml of HCl and 49 ml of CH_3OH) at 37°C
25 and is stirred for 7 minutes. (1 ml of acid HPF_6 , HBF_4 or HAuCl_4) is added and the solution is cooled to 10°C . Crystals of the sulphenamide with the general formula IIIa are precipitated, filtered off and dried.

Method b)

30

0.005 mole of a sulfoxide with the general formula Ia is dissolved in 50 ml of 0.2 M HCl in CH_3OH (1 ml of HCl and 49 ml of CH_3OH) at 37°C and is stirred for 7 min. The solution is cooled, whereby a sulphenamide with the general formula IIIa is precipitated as its Cl^- -salt. The pre-
35 cipitate is filtered off and dried.

Method b)

- 0.01 mole of a sulfoxide with the general formula Ia is dissolved in 100 ml 0.2M methanolic HBF_4 (2.5 ml 50% HBF_4 and 97.5 ml of CH_3OH) at 37°C and is stirred for 2 min. 50 ml of MeOH is added and the mixture is then stirred for another 3 min at 37°C. The mixture is cooled to 5°C. Crystals of the sulphenamide with the general formula IIIa are precipitated, filtered off and dried.
- 10 The invention also relates to pharmaceutical compositions containing the new sulphenamides as active ingredient; to the use of the novel sulphenamides in therapy, especially for providing gastrointestinal cytoprotective effects in mammals and man; to the use of the novel sulphenamides in the prevention and treatment of gastrointestinal inflammatory diseases in mammals and man; to a method for inhibiting gastric acid secretion in mammals and man by administering a compound of the formula IIIa; to a method for the treatment of gastrointestinal inflammatory diseases in mammals and man by administering a compound of the formula IIIa; and to a method for providing gastrointestinal cytoprotective effects in mammals and man by administering a compound of the formula IIIa.

- For clinical use the compounds of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other mode of administration. The pharmaceutical formulation contains a compound of the invention in combination with a pharmaceutically acceptable carrier. The carrier may be in the form of a solid, semisolid or liquid diluent, or a capsule. These pharmaceutical preparations are a further object of the invention. Usually the amount of active compound is between 0.1-95% by weight of the preparation.

- In the preparation of pharmaceutical formulations containing a compound of the present invention in the form of dosage units for oral administration the compound selected may be mixed with a solid, powdered carrier, e.g. calcium phosphate, lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives or gelatin, as well as with lubri-

cating agents e.g. magnesium stearate, calcium stearate, sodium steryl fumarate and polyethylene glycol waxes. The mixture is then processed into granules or pressed into tablets. The tablets may be film coated by a suitable film-forming material.

5

Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention and a suitable vehicle for soft gelatine capsules. Hard gelatine capsules may also contain the active compound in combination with a solid powdered carrier
10 e.g. lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine.

The oral dosage forms may be enteric coated. The enteric coating is chosen among pharmaceutically acceptable enteric-coating materials e.g.
15 beeswax, shellac or anionic film-forming polymers such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, partly methyl esterified methacrylic acid polymers and the like, if preferred in combination with a suitable plasticizer. To this coating various dyes may be added in order to distinguish among tablets or granules
20 with different active compounds or with different amounts of the active compound present.

The typical daily dose of the active substance varies within a wide range and will depend on various factors such as for example the individual
25 requirement of each patient, the manner of administration and the disease. In general, oral and parenteral dosages will be in the range of 1 to 400 mg per day of active substance.

Example 1A + 1B. 2,4-Dimethyl-3,9-dimethoxy-5H-pyrido[1',2':4,5][1,2,4]-
30 thiadiazino[2,3-a]benzimidazol-13-ium tetrafluoroborate (1A) and
2,4-Dimethyl-3,10-dimethoxy-5H-pyrido[1',2':4,5][1,2,4]thiadiazino-
[2,3-a]benzimidazol-13-ium tetrafluoroborate (1B) (isomeric mixture)

Method a

35

5-Methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphonyl]-
1H-benzimidazole (1.72 g, 0.005 mol) was dissolved in 0.2M methanolic
HCl (50 ml) (1 ml conc. HCl and 49 ml CH₃OH) and stirred at 37°C for

0171372

7 min. Conc. HBF_4 (1 ml) was added and the solution was cooled to 10°C . The desired mixture of the isomeric sulphenamide products was filtered off as a crystalline material and dried. Yield: 1.25 g (60%). NMR. See Table 2.

5

Method b

5-Methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphonyl]-
 1H-benzimidazole (3.45 g, 0.01 mol) was dissolved in 0.2M methanolic
 10 HBF_4 (100 ml) (2.5 ml 50% HBF_4 and 97.5 ml CH_3OH) and stirred at 37°C
 for 2 min. More methanol (50 ml) was added and the mixture was stirred
 for another 3 min at 37°C . The mixture was cooled to 5°C , whereupon
 the desired mixture of isomeric sulphenamide products (1A + 1B) precipit-
 ated out. The product in the form of an isomeric mixture was filtered
 15 off and dried, yielding 3.3 g (79%). NMR: See Table 2.

Example 11. 3-Methoxy-4,9,10-trimethyl-5H-pyrido[1',2':4,5][1,2,4]thia-
diazino[2,3-a]benzimidazol-13-ium chloride (11)

(Method b)

20

5,6-Dimethyl-2-[[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulphonyl]-1H-
 benzimidazole (1.60 g, 0.005 mol) was dissolved in 0.2M methanolic HCl
 (50 ml) (1 ml conc. HCl and 49 ml CH_3OH) and stirred at 37° for 7 min.
 The solution was cooled and the desired sulphenamide salt precipitated.
 25 The product was filtered off and dried, yielding 0.3 g (17%). NMR: See
 Table 2.

Example 12. Benzimidazo[1,2-b]pyrido[1,2,3-de][1,2,4]benzothiadiazin-
-14-ium, hexafluorophosphate (12)

30

(Method a)

2-[8-quinolinyl]-sulphonyl-1H-benzimidazole (1.50 g, 0.005 mol) was
 dissolved in 0.2M methanolic HCl (50 ml) (1 ml conc. HCl and 49 ml
 35 CH_3OH) and the solution was stirred at 37° for 7 min. Conc. HPF_6 (1 ml)
 was added and the solution was cooled to 10°C . The desired sulphenamide
 salt was filtered off as a crystalline material and dried.
 M.p. 199°C .

The starting compound was prepared according to the following method.

Preparation of 2-[8-quinoliny]-thio-1H-benzimidazole

To 8-mercaptoquinoline hydrochloride (5.00 g, 0.025 mol) in ethanol (250 ml) conc. HCl (2.25 ml) and 2-chlorobenzimidazole (3.86 g, 0.025 mol) were added. The mixture was refluxed overnight. pH was adjusted to 13.0 by addition of 2M NaOH. Part of the solvent was evaporated off. The mixture was poured on ice-water. Filtration and recrystallization from CH_3CN gave the desired product (4.50 g, 65%), m.p. 215°C.


10 Preparation of 2-[8-quinoliny]-sulphonyl-1H-benzimidazole

m-Chloroperbenzoic acid, 82% (3.42 g, 0.016 mol) dissolved in CH_2Cl_2 (100 ml) and cooled to -10°C was added under stirring to 2-[8-quinoliny]-thio-1H-benzimidazole (4.50 g, 0.016 mol) dissolved in CH_2Cl_2 (150 ml) maintaining the temperature at -5°C. Stirring was continued at -5°C for 10 min. The CH_2Cl_2 -solution was washed with NaHCO_3 (2.69 g, 0.032 mol) dissolved in water (100 ml). The organic phase was dried (Na_2SO_4), filtered and the solvent was evaporated off. CH_3CN was added to the residue and the mixture was warmed under stirring. The precipitate was filtered off and washed with warm CH_3CN , giving the desired product (2.40 g, 51%), m.p. 205°C.

0171372

Table 1

Representative examples of compounds included in the scope of the invention.



Example No.	R ^{1a}	R ^{2a}	R ^{3a}	R ^{4a}	R ^{5a}	R ^{6a}	R ^{7a}	R ^{8a}	X [⊖]	Identified by M.p. °C or NMR
1A	H	-OCH ₃	H	H	H	-CH ₃	-OCH ₃	-CH ₃	BF ₄	NMR
1B	H	H	-OCH ₃	H	H	-CH ₃	-OCH ₃	-CH ₃	BF ₄	NMR
2A	H	-OCH ₃	H	H	H	-CH ₃	-OCH ₃	-CH ₃	PF ₆	NMR
2B	H	H	-OCH ₃	H	H	-CH ₃	-OCH ₃	-CH ₃	PF ₆	NMR
3A	H	-OCH ₃	H	H	H	-CH ₃	-OCH ₃	-CH ₃	AuCl ₄	NMR
3B	H	H	-OCH ₃	H	H	-CH ₃	-OCH ₃	-CH ₃	AuCl ₄	NMR
4	H	H	H	H	H	-CH ₃	-OCH ₃	-CH ₃	PF ₆	NMR
5	H	H	H	H	H	-CH ₃	-OCH ₃	-CH ₃	AuCl ₄	NMR
6	H	H	H	H	H	H	H	H	BF ₄	225
7A	H	-CH ₃	H	H	-CH ₃	H	H	H	BF ₄	NMR
7B	H	H	-CH ₃	H	-CH ₃	H	H	H	BF ₄	NMR
8	H	-CH ₃	-CH ₃	H	-CH ₃	H	H	H	BF ₄	NMR
9	H	-CH ₃	-CH ₃	H	H	H	-OCH ₃	H	BF ₄	187



0171372

Table 1 cont.

Example No.	R ^{1a}	R ^{2a}	R ^{3a}	R ^{4a}	R ^{5a}	R ^{6a}	R ^{7a}	R ^{8a}	X [⊖]	Identified by M.P. °C or NMR
10	H	-CH ₃	-CH ₃	H	H	-CH ₃	-OCH ₃	H	BF ₄	NMR
11	H	-CH ₃	-CH ₃	H	H	-CH ₃	-OCH ₃	H	Cl	NMR
12	H	H	H	H	=CH-CH=CH-	-CH ₃	H	H	BF ₄	199
13	H	-CH ₃	-CH ₃	H	H	-CH ₃	H	-CH ₃	PF ₆	NMR
14	H	H	H	H	H	-CH ₃	-CH ₃	H	BF ₄	215
15	H	H	H	H	H	-CH ₃	-CH ₃	H	Cl	170
16	-CH ₃	-CH ₃	-CH ₃	-CH ₃	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	Cl	
17	-CH ₃	-CH ₃	-CH ₃	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	PF ₆	
18	H	-CH ₃	-CH ₃	-CH ₃	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	BF ₄	
19	H	-CH ₃	-CH ₃	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	AuCl ₄	
20	-CH ₃	H	-CH ₃	-CH ₃	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	PF ₆	
21	-CH ₃	H	-CH ₃	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	BF ₄	
22	H	H	-CH ₃	-CH ₃	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	AuCl ₄	
23	H	-CH ₃	-CH ₃	H	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	Cl	
24	-CH ₃	H	H	-CH ₃	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	Cl	
25	H	H	H	-CH ₃	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	BF ₄	
26	H	H	-CH ₃	H	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	AuCl ₄	
27	H	H	-OCH ₃	H	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	PF ₆	
28	H	H	-OCH ₃	H	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	Cl	
29	H	H	-OCH ₃	H	H	-CH ₃	-OCH ₂ C≡CH	-CH ₃	AuCl ₄	
30	H	H	-OCH ₃	H	H	-CH ₃	-O(CH ₂) ₃ CH=CH ₂	-CH ₃	Cl	
31	H	H	-OCH ₃	H	H	-CH ₃	-O(CH ₂) ₃ CH ₃	-CH ₃	PF ₆	
32	H	H	-OCH ₃	H	H	-CH ₃	-OCH(CH ₃) ₂	-CH ₃	BF ₄	



0171372

Table 1 (cont.)

Example No.	R ^{1a}	R ^{2a}	R ^{3a}	R ^{4a}	R ^{5a}	R ^{6a}	R ^{7a}	R ^{8a}	X [⊖]	Identified by M.p. °C or NMR
33	H	H	-OCH ₃	H	H	-CH ₃	-OCH ₂ CH ₂ CH(CH ₃) ₂	-CH ₃	Cl	
34	H	-CH ₃	-OCH ₃	-CH ₃	H	H	-CH(CH ₃) ₂	-CH ₃	PF ₆	
35	H	-CH ₃	H	-CH ₃	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	BF ₄	
36	H	H		H	H	-CH ₃	-OCH ₃	-CH ₃	AuCl ₄	
37	H	H	-OCH ₂ CH ₂ - 	H	H	-CH ₃	-OCH ₃	-CH ₃	PF ₆	
38	H	-CH ₃	-COOCH ₃	H	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	BF ₄	
39	H	H	-CH(CH ₃) ₂	H	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	Cl	
40	H	H	-C(CH ₃) ₃	H	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	AuCl ₄	
41	H	-CH ₃	-OCH ₃	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	BF ₄	
42	H	-CH ₃	-OCH ₃	-CH ₃	H	-CH ₃	-CH ₃	H	AuCl ₄	
43	H	-CH ₃	-COCH ₃	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	PF ₆	
44	H	-CH ₃	-COCH ₃	-CH ₃	H	-CH ₃	H	-CH ₃	Cl	
45	H	-CH ₃	-COC ₂ H ₅	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	AuCl ₄	
46	H	-CH ₃	-CH ₃	-CH ₃	-CH ₃	-CH ₃	-OCH ₃	-CH ₃	BF ₄	
47	H	-CH ₃	-CH ₃	-CH ₃	H	-CH ₃	-CH ₃	-CH ₃	PF ₆	
48	H	-CH ₃	-C ₂ H ₅	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	Cl	
49	H	-CH ₃	-C ₂ H ₅	-CH ₃	H	-CH ₃	-OCH ₃	H	PF ₆	
50	H	-CH ₃	-CH(CH ₃) ₂	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	BF ₄	


0171372

Table 1 (cont.)

Example No.	R ^{1a}	R ^{2a}	R ^{3a}	R ^{4a}	R ^{5a}	R ^{6a}	R ^{7a}	R ^{8a}	X [⊖]	Identified by M.p. °C or NMR
51	H	-CH ₃	-CH(CH ₃) ₂	-CH ₃	H	-CH ₃	-CH ₃	-CH ₃	AuCl ₄	
52	H	-OCH ₃	-Br	-OCH ₃	H	-CH ₃	-OCH ₃	-CH ₃	PF ₆	
53	H	-OCH ₃	-Br	-OCH ₃	H	-CH ₃	-CH ₃	H	BF ₄	
54	H	-C ₂ H ₅	-CN	-C ₂ H ₅	H	-CH ₃	-OCH ₃	H	AuCl ₄	
55	H	-C ₂ H ₅	-CN	-C ₂ H ₅	H	-CH ₃	-OC ₂ H ₅	-CH ₃	Cl	
56	-CH ₃	-CH ₃	-OCH ₃	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	Cl	
57	-CH ₃	H	-OCH ₃	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	BF ₄	
58	-CH ₃	H	-OCH ₃	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	AuCl ₄	
59	-OCH ₃	H	-OCH ₃	-Cl	H	-CH ₃	-OCH ₃	-CH ₃	PF ₆	
60	H	-Cl	-Cl	-Cl	H	-CH ₃	-OCH ₃	-CH ₃	Cl	
61	H	-CH ₃	-CH ₃	H	H	H	-OCH ₃	-C ₂ H ₅	AuCl ₄	
62	H	-CH ₃	-O(CH ₂) ₆ CH ₃	-CH ₃	H	-CH ₃	-OCH ₃	-CH ₃	Cl	
63	H	H	-C ₂ H ₅	H	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	PF ₆	
64	H	H	-OCH ₃	H	H	-CH ₃	-O(CH ₂) ₂ CH(CH ₃) ₂	-CH ₃	BF ₄	
65	H	H	-C(CH ₃) ₃	H	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	Cl	
66	H	H		H	H	-CH ₃	-OCH ₃	-CH ₃	PF ₆	
67	H	H	-NO ₂	H	H	-CH ₃	-OCH ₃	-CH ₃	BF ₄	
68	H	H	-Br	H	H	-CH ₃	-OCH ₂ CH=CH ₂	-CH ₃	AuCl ₄	
69	H	-CH ₃		H	H	H	-OCH ₃	-C ₂ H ₅	PF ₆	



0171372

Table 1 (cont.)

Example No.	R ^{1a}	R ^{2a}	R ^{3a}	R ^{4a}	R ^{5a}	R ^{6a}	R ^{7a}	R ^{8a}	X [⊖]	Identified by M.p. °C or NMR
70	H	-CH ₃	-CH ₃	-CH ₃	H	-CH ₃	-CH ₃	H	BF ₄	
71	H	-CH ₃	-CH ₃	-CH ₃	H	H	-CH ₃	-CH ₃	Cl	
72	H	-CH ₃	-CH ₃	-CH ₃	H	-CH ₃	H	-CH ₃	AuCl ₄	
73	-CH ₃	H	-CH ₃	-CH ₃	H	-CH ₃	-CH ₃	H	BF ₄	
74	H	-CH ₃	-CN	-CH ₃	H	-CH ₃	-OC ₂ H ₅	-CH ₃	AuCl ₄	
75	H	H	-OCH ₃	-CH ₃	H	H	-OCH ₃	-C ₂ H ₅	PF ₆	
76	H	-CH ₃	H	-CH ₃	H	H	-OCH ₂ CH=CH ₂	-CH ₃	Cl	
77	H	H	-CF ₃	H	H	-CH ₃	-OCH ₃	-CH ₃	AuCl ₄	
78	H	H	-NO ₂	H	H	-CH ₃	-OCH ₃	-CH ₃	BF ₄	
79	H	H	-Cl	H	H	-CH ₃	-OCH ₃	-CH ₃	PF ₆	
80	H	H	H	H	H	-CH ₂ CH ₂ CH ₂ O-		H	PF ₆	
81	H	OCH ₃	H	H	H	-CH ₂ CH ₂ CH ₂ O-		H	PF ₆	
82	H	H	H	H	H	-CH ₂ CH ₂ CH ₂ CH ₂ O-		H	Cl	
83	H	OCH ₃	H	H	H	-CH ₂ CH ₂ CH ₂ CH ₂ -		H	BF ₄	
84	H	H	H	H	H	-CH ₂ CH ₂ CH ₂ CH ₂ -		H	PF ₆	
85	H	OCH ₃	H	H	H	-CH ₂ CH ₂ CH ₂ CH ₂ S-		H	PF ₆	
86	H	-OCF ₂ CHFO-		H	H	H	-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ -	H	PF ₆	
87	H	-OCF ₃ CHFO-		H	H	CH ₃	OCH ₃	H	PF ₆	
88	H	-OCF ₂ O-		H	H	H	OCH ₃	H	PF ₆	
89	H	-OCF ₂ O-		H	H	CH ₃	OCH ₃	H	Br	
90	H	-OCF ₂ O-		H	H	H	OCH ₃	H	Cl	
91	H	-OCF ₂ CFCF ₁₀ -		H	H	CH ₃	OCH ₃	CH ₃	Cl	
92	H	-CO- 	H	H	H	CH ₃	OCH ₃	H	BF ₄	

0171372

Table 1 (cont.)

Example No.	R ^{1a}	R ^{2a}	R ^{3a}	R ^{4a}	R ^{5a}	R ^{6a}	R ^{7a}	R ^{8a}	X [⊖]	Identified by M.p. °C or NMR
93	H	-CO- 	H	H	H	H	OCH ₃	H	I	
94	H	-CO- 	H	H	H	CH ₃	OCH ₃	H	BF ₄	
95	H	OCF ₃	H	H	H	CH ₃	OCH ₃	H	PF ₆	
96	H	OCF ₃	H	H	H	H	OCH ₃	H	Cl	
97	H	OCF ₃	H	H	H	H	OCH ₃	CH ₃	PF ₆	
98	H	OCF ₃	H	H	H	CH ₃	OCH ₃	CH ₃	Cl	
99	H	OCF ₂ CHF ₂	H	H	H	CH ₃	OCH ₃	H	Br	
100	H	OCF ₂ CHF ₂	H	H	H	H	OCH ₃	H	Cl	
101	H	OCF ₂ CHF ₂	H	H	H	H	OCH ₃	CH ₃	PF ₆	
102	H	OCF ₂ CF ₃	H	H	H	CH ₃	OCH ₃	H	PF ₆	
103	H	OCHF ₂	H	H	H	CH ₃	OCH ₃	H	PF ₆	
104	H	OCHF ₂	OCHF ₂	H	H	H	OCH ₃	H	PF ₆	
105	H	OCHF ₂	OCH ₃	H	H	CH ₃	OCH ₃	H	PF ₆	

0171372

Identifying data for the compounds according to the examples 1-5, 7, 8, 10, 11 and 13 are given in the following table 2.

Table 2.

5	Compound according to example	NMR data (90 MHz)	
		δ ppm	(CD ₃ CN)
10	1 A } isomeric	2.53(s,3H), 2.63(s,3H), 3.97(s,3H), 4.37(s,3H),	
	1 B } mixture	4.90(s,2H), 6.97-7.83(m,3H), 9.30(s,1H)	
	2 A } isomeric	2.53(s,3H), 2.63(s,3H), 3.93(s,3H), 4.37(s,3H),	
	2 B } mixture	4.90(s,2H), 7.0-7.83(m,3H), 9.30(s,1H)	
15	3 A } isomeric	2.50(s,3H), 2.60(s,3H), 3.90(s,3H), 4.30(s,3H),	
	3 B } mixture	4.83(s,2H), 7.0-7.80(m,3H), 9.30(s,1H)	
20	4	2.50(s,3H), 2.63(s,3H), 4.37(s,3H), 4.87(s,2H),	
		7.30-7.60(m,3H), 7.6-8.0(m,1H), 9.37(s,1H)	
	5	2.47(s,3H), 2.60(s,3H), 4.33(s,3H), 4.87(s,2H),	
		7.10-7.70(m,3H), 7.73-8.0(m,1H), 9.37(s,1H)	
25	7 A } isomeric	1.57(d,3H), 2.50 and 2.53 (2s, totally 3H),	
	7 B } mixture	5.20(q,1H), 7.27-7.50(m,2H), 7.60-7.83(m,1H),	
		8.13-8.33(m,2H), 8.70-8.97(m,1H), 9.67(d,1H)	
30	8	1.60(d,3H), 2.47(s,3H), 2.50(s,3H), 5.23(q,1H),	
		7.50(s,1H), 7.77(s,1H), 8.33(s,1H), 8.43(s,1H),	
		8.90(d,1H), 9.80(d,1H)	
35	10	2.46(s,9H), 4.30(s,3H), 4.83(s,2H), 7.40-7.80	
		(m,3H), 9.50(d,1H)	
	11	2.43(s,6H), 2.47(s,3H), 4.30(s,3H), 4.97(s,2H),	
		7.20(s,2H), 7.40(d,1H), 9.50(d,1H)	
40	13	2.43(s,3H), 2.50(s,3H), 2.63(s,3H), 2.70(s,3H),	
		4.90(s,2H), 7.50(s,1H), 7.70(s,1H), 8.60(s,1H),	
		9.47(s,1H)	

Incorporation of the new sulphenamides of the present invention in pharmaceutical preparations is exemplified by the following example.

Example 80. Tablets

5

3-Methoxy-4,9,10-trimethyl-5-H-pyrido[1',2':4,5]/[1,2,4]thiadiazino-[2,3-a]-benzimidazol-13-ium chloride (250 g), was mixed with

10

500 g lactose anhydrous
500 g microcrystalline cellulose
100 g crosslinked polyvinylpyrrolidone

in a mixer. 5 g of magnesium stearate was admixed and the mixture was pressed into tablets each weighing 275 mg.

15

Biological tests

1. In vitro inhibition of gastric H^+, K^+ -ATPase

20

Hog gastric H^+, K^+ -ATPase was purified according to Saccomani et al., Biochim. Biophys. Acta 465, 311-330, 1977. 10 μ g of membrane protein (G1-fraction in the reference listed above) was incubated with 2 mmol/l of piperazine-N,N'-bis-(2-ethane sulfonic acid) buffer pH 7,4 and the test compound in concentrations 10^{-7} - 10^{-4} M in a final volume of 1 ml.

25

(The test compound was dissolved in methanol. Aliquots of these stock solutions were diluted to a final methanol concentration below 1%, which on its own had no effect on the enzyme activities.) After 30 minutes of incubation, the remaining H^+, K^+ -ATPase activity was determined, according to Wallmark et al., Biochim. Biophys. Acta, 728, 31-38, 1983. A dose-response curve was constructed and the concentration at half-maximal inhibition (IC_{50}) could be determined. When testing the isomeric mixture from Examples 1A and 1B an $IC_{50} = 6.10^{-7}$ M was obtained.

30

II. Inhibiting effect in vivo on gastric acid secretion in conscious dog

Test Method

5 Chronic gastric fistula dogs were used. These dogs have been surgically provided with a gastric cannula in the stomach and a duodenal fistula used for direct intraduodenal administration of test compounds. Following a 4 weeks' recovery period after surgery, tests were performed once a week on each dog. Food and water were withdrawn 18 hours before each
10 test.

The test compound was suspended in 0.5% Methocel® (90 HG, 15.000, Dow Chem Corp.), the pH was immediately adjusted to about 4 by addition of hydrochloric acid and the suspension administered orally by using
15 a stomach tube. After 1 hour gastric acid secretion was induced by continuous infusion of histamine at individual doses (400-600 nmol/kg, h), resulting in approx. 90% of maximal secretion of gastric acid. The gastric juice was collected by free flow from the gastric cannula in consecutive 30 minutes samples for 2 hours. The samples were titrated
20 to pH 7.0 with 0.1 M NaOH using a Radiometer automatic titrator and the acid output was calculated. The per cent inhibition of acid secretion was calculated by comparing in each dog the acid output in the tests to the acid output in control tests when only the vehicle was given. The peak inhibitory effect for each compound was determined.
25 When testing the isomeric mixture from Examples 1A and 1B at a concentration of 4 µmol/kg an inhibition of 40% was obtained.

III. In vivo cytoprotective effect: Effect on ethanol-induced gastric lesions in the rat

30

Two groups of female Sprague-Dawley rats (190-220 g) were used, one for the test compound and one for the control experiment. Food, but not water, was removed 24 h before the experiments.

35 The animals in the test group were treated orally with the test compound dissolved in 0.01 M HCl immediately before the test and the animals in the control group were given the vehicle (0.01 M HCl) in a dose of 1 ml/kg.

Five or thirty minutes later the rats were given orally 1 ml of absolute ethanol (a standard agent for inducing gastric mucosal lesions).


5 Thirty minutes later the rats were killed by carbon dioxide asphyxiation, their stomachs dissected out and the gastric mucosae were examined for the presence of necrotic lesions. The total lengths of the lesions in the stomachs were measured in the test group and in the control group, in both cases treated five and thirty minutes before with ethanol.

10 When testing the isomeric mixture from Example 1A and 1B at a dose of 20 $\mu\text{mol/kg}$ the total lengths of lesions in the stomachs were reduced to 5.3 cm (5 min) and 4.4 cm (30 min) compared to the lesions of the controls, which were 11.4 cm (5 min) and 10.4 cm (30 min). This indicates an ED_{50} -value below 20 $\mu\text{mol/kg}$.

15 The biological tests thus show that the compounds with the general formula IIIa both inhibit gastric acid secretion and have a gastrointestinal cytoprotecting effect.

CLAIMS FOR ALL CONTRACTING STATES EXCEPT AT

1. A compound of the formula IIIa



wherein R^{1a} , R^{2a} , R^{3a} and R^{4a} are the same or different and are hydrogen, an alkyl, alkoxy optionally completely or predominantly substituted by fluorine or chlorine, halogen, $-CN$, $-CF_3$, $-NO_2$, $-COR$, $-COOR$, aryl, aryloxy or arylalkoxy group, or adjacent groups R^{1a} , R^{2a} , R^{3a} and R^{4a} together with the adjacent carbon atoms in the benzimidazole ring form a 5-, 6- or 7-membered monocyclic ring or a 9-, 10- or 11-membered bicyclic ring, which rings may be saturated or unsaturated and may contain 0-3 heteroatoms selected from N and O and which rings may be optionally substituted with 1-4 substituents selected from alkyl groups with 1-3 carbon atoms, halogen preferably F or Cl, alkylene radicals containing 4-5 carbon atoms giving spiro compounds, or two or four of these substituents together form one or two oxy groups

30

35

($-\overset{\overset{O}{\parallel}}{C}-$), whereby if R^{1a} , R^{2a} , R^{3a} and R^{4a} together with the adjacent carbon atoms in the benzimidazole ring form two rings they may be condensed with each other, R^{5a} is hydrogen or an alkyl group, R^{6a} is hydrogen or an alkyl group or R^{5a} and R^{6a} are joined together to form an alkylene chain, R^{7a} is hydrogen, an alkyl, alkoxy, alkenyloxy or alkynyloxy group, R^{8a} is hydrogen or an alkyl group, or R^{6a} and R^{7a} , or R^{7a} and R^{8a} together with the adjacent carbon atoms in the pyridinium ring form a ring wherein the part constituted by R^{6a} and R^{7a} or R^{7a} and R^{8a} , is $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$, $-\text{O}-(\text{CH}_2)_p-$, $-\text{CH}_2(\text{CH}_2)_p-$, $-\text{O}-\text{CH}=\text{CH}-$, $-\text{NH}-\text{CH}=\text{CH}-$, $-\text{N}-\text{CH}=\text{CH}-$, $-\text{CH}_3$

or $-S-(CH_2)_p^-$, wherein p is 2, 3 or 4 and the O, S and N atoms always are attached to position 3 in the compound IIIa, R is an alkyl, cycloalkyl, aryl or arylalkyl group, and X^- is a pharmaceutically acceptable anion.

5

2. A compound according to claim 1, wherein the pharmaceutically acceptable anion is Cl^- , Br^- , I^- , BF_4^- , PF_6^- or $AuCl_4^-$.

10

15

20

25

3. A compound according to claims 1-2 wherein R^{1a} , R^{2a} , R^{3a} and R^{4a} are the same or different and are each hydrogen, a lower alkyl group having 1-7 carbon atoms, a lower alkoxy group having 1-7 carbon atoms, chloro, bromo, fluoro or iodo, an aryl group having up to 10 carbon atoms, an aryloxy group having up to 10 carbon atoms, an aralkoxy group having up to 10 carbon atoms in the aryl group and 1-5 carbon atoms in the alkoxy group, $-COR$ and/or $-COOR$, wherein R is a lower alkyl group having 1-7 carbon atoms, a cycloalkyl having 3-10 carbon atoms, an aryl having preferably up to 10 carbon atoms or an arylalkyl group having up to 10 carbon atoms in the aryl group and 1-7 carbon atoms in the alkyl group, R^{5a} is hydrogen or a lower alkyl group having 1-7 carbon atoms, R^{6a} is hydrogen or a lower alkyl group having 1-7 carbon atoms or R^{5a} and R^{6a} are joined together to form an alkenylene chain having 3 carbon atoms, R^{7a} is hydrogen, a lower alkyl group having 1-7 carbon atoms, an alkoxy group having 1-7 carbon atoms, an alkenyloxy or an alkynyloxy group each having 2-5 carbon atoms and R^{8a} is hydrogen or a lower alkyl group having 1-7 carbon atoms.

30


4. A compound according to claims 1-3 wherein each of R^{1a} , R^{4a} , R^{5a} and R^{8a} is hydrogen, each of R^{2a} and R^{3a} is methyl, R^{7a} is methoxy, R^{6a} is hydrogen or methyl and X^- is BF_4^- .

5. A compound according to claims 1-3 wherein each of R^{1a} , R^{3a} , R^{4a} and R^{5a} is hydrogen, each of R^{6a} and R^{8a} is methyl, R^{7a} is methoxy, R^{2a} is hydrogen or methoxy and X^- is PF_6^- or $AuCl_4^-$.


35

6. The isomeric mixture of 2,4-dimethyl-3,9-dimethoxy-5H-pyrido-[1',-2':4,5][1,2,4]-thiadiazino[2,3-a] benzimidazol-13-ium tetrafluoroborate and 2,4-dimethyl-3,10-dimethoxy-5H-pyrido[1',2':4,5][1,2,4]-thiadiazino-[2,3-a] benzimidazol-13-ium tetrafluoroborate.

7. A process for the preparation of a compound of the formula IIIa



15 wherein R^{1a} , R^{2a} , R^{3a} , R^{4a} , R^{5a} , R^{6a} , R^{7a} and R^{8a} and X^{\ominus} are as defined in claim 1, characterized by reacting under transformation a compound of the general formula Ia




30 either a) acid catalyzed or b) non-acid catalyzed to form the salt of the formula IIIa.

8. A process according to claim 7 wherein the reaction is catalyzed by an acid.

35 9. A process according to claim 7 and 8 wherein the reaction is catalyzed by HPF_6 , HBF_4 or $HAuCl_4$.

10. A compound with the general formula Ia



wherein R^{1a}, R^{2a}, R^{3a}, R^{4a}, R^{7a} and R^{8a} are as defined in claim 1 and
 15 R^{5a} and R^{6a} are joined together under the formation of an alkenylene chain having 3 carbon atoms.

11. A pharmaceutical composition containing as active ingredient a compound according to any of the claims 1-6.

20

12. A compound as defined in any of the claims 1-6 for use in inhibiting gastric acid secretion in mammals and man.

13. A compound as defined in any of the claims 1-6 for use as gastro-
 25 intestinal cytoprotecting agent in mammals and man.


14. A compound as defined in any of the claims 1-6, for use in the treatment of gastrointestinal inflammatory diseases in mammals and man.

30 15. Use of a compound of the general formula IIIa according to claim 1 for the manufacture of a pharmaceutical preparation for inhibiting gastric acid secretion.

16. Use of a compound of the general formula IIIa according to claim
 35 1 for the manufacture of a pharmaceutical preparation for treatment of gastrointestinal inflammatory diseases.

17. Use of a compound of the general formula IIIa according to claim 1 for the manufacture of a pharmaceutical preparation having gastrointestinal cytoprotective effect.


1. A process for the preparation of a compound of the formula IIIa



30 (-C-), whereby if R^{1a}, R^{2a}, R^{3a} and R^{4a} together with the adjacent carbon atoms in the benzimidazole ring form two rings they may be condensed with each other, R^{5a} is hydrogen or an alkyl group, R^{6a} is hydrogen or an alkyl group or R^{5a} and R^{6a} are joined together to form an alkylene chain, R^{7a} is hydrogen, an alkyl, alkoxy, alkenyloxy or alkynyloxy group, R^{8a} is hydrogen or an alkyl group, or R^{6a} and R^{7a}, or R^{7a} and R^{8a} together with the adjacent carbon atoms in the pyridinium ring form a ring wherein the part constituted by R^{6a} and R^{7a} or R^{7a} and R^{8a}, is
35 -CH=CH-CH=CH-, -O-(CH₂)_p-, -CH₂(CH₂)_p-, -O-CH=CH-, -NH-CH=CH-, -N-CH=CH-,
CH₃

or $-S-(CH_2)_p-$, wherein p is 2, 3 or 4 and the O, S and N atoms always are attached to position 3 in the compound IIIa, R is an alkyl, cycloalkyl, aryl or arylalkyl group, and X^- is a pharmaceutically acceptable anion, characterized by reacting under transformation a compound of

5 the general formula Ia



Ia

either a) acid catalyzed or b) non-acid catalyzed to form the salt of the formula IIIa.

2. A process according to claim 1, wherein the pharmaceutically acceptable anion is Cl^- , Br^- , I^- , BF_4^- , PF_6^- or $AuCl_4^-$.

3. A process according to claims 1-2 wherein R^{1a} , R^{2a} , R^{3a} and R^{4a} are the same or different and are each hydrogen, a lower alkyl group having 1-7 carbon atoms, a lower alkoxy group having 1-7 carbon atoms, chloro, bromo, fluoro or iodo, an aryl group having up to 10 carbon atoms, an aryloxy group having up to 10 carbon atoms, an aralkoxy group having up to 10 carbon atoms in the aryl group and 1-5 carbon atoms in the alkoxy group, $-COR$ and/or $-COOR$, wherein R is a lower alkyl group having 1-7 carbon atoms, a cycloalkyl having 3-10 carbon atoms, an aryl having preferably up to 10 carbon atoms or an arylalkyl group having up to 10 carbon atoms in the aryl group and 1-7 carbon atoms in the alkyl group, R^{5a} is hydrogen or a lower alkyl group having 1-7 carbon atoms, R^{6a} is hydrogen or a lower alkyl group having 1-7 carbon atoms or R^{5a} and R^{6a} are joined together to form an alkenylene chain having 3 carbon atoms, R^{7a} is hydrogen, a lower alkyl group having 1-7 carbon atoms, an alkoxy group having 1-7 carbon atoms, an alkenyloxy or an

alkynyloxy group each having 2-5 carbon atoms and R^{8a} is hydrogen or a lower alkyl group having 1-7 carbon atoms.

4. A process according to claims 1-3 wherein each of R^{1a} , R^{4a} , R^{5a} and R^{8a} is hydrogen, each of R^{2a} and R^{3a} is methyl, R^{7a} is methoxy, R^{6a} is hydrogen or methyl and X^- is BF_4^- .


5. A process according to claims 1-3 wherein each of R^{1a} , R^{3a} , R^{4a} and R^{5a} is hydrogen, each of R^{6a} and R^{8a} is methyl, R^{7a} is methoxy, R^{2a} is hydrogen or methoxy and X^- is PF_6^- or $AuCl_4^-$.

6. A process according to claim 1, wherein the isomeric mixture of 2,4-dimethyl-3,9-dimethoxy-5H-pyrido-[1',2':4,5][1,2,4]-thiadiazinol[2,3-a] benzimidazol-13-ium tetrafluoroborate and 2,4-dimethyl-3,10-dimethoxy-5H-pyrido[1',2':4,5][1,2,4]-thiadiazinol[2,3-a] benzimidazol-13-ium tetrafluoroborate is prepared.

7. A process according to claim 1 wherein the reaction is catalyzed by an acid.

8. A process according to claim 1 and 7 wherein the reaction is catalyzed by HPF_6 , HBF_4 or $HAuCl_4$.

9. A process according to claim 1 wherein a compound with the general formula Ia



Ia

wherein R^{1a} , R^{2a} , R^{3a} , R^{4a} , R^{7a} and R^{8a} are as defined in claim 1 and R^{5a} and R^{6a} are joined together under the formation of an alkenylene chain having 3 carbon atoms is used as the starting compound.

- 5 10. A process for the preparation of a pharmaceutical composition containing as active ingredient a compound according to any of the claims 1-6, characterized in that the active compound of the formula IIIa is mixed with one or more carriers to a pharmaceutical composition.
- 10 11. A process according to any of the claims 1-8, wherein the compound obtained is for use in inhibiting gastric acid secretion in mammals and man.
- 15 12. A process according to any of the claims 1-8, wherein the compound obtained is for use as gastrointestinal cytoprotecting agent in mammals and man.
- 20 13. A process according to any of the claims 1-8, wherein the compound obtained is for use in the treatment of gastrointestinal inflammatory diseases in mammals and man.
- 25 14. Use of a compound of the general formula IIIa according to claim 1 for the manufacture of a pharmaceutical preparation for inhibiting gastric acid secretion.
- 30 15. Use of a compound of the general formula IIIa according to claim 1 for the manufacture of a pharmaceutical preparation for treatment of gastrointestinal inflammatory diseases.
- 35 16. Use of a compound of the general formula IIIa according to claim 1 for the manufacture of a pharmaceutical preparation having gastrointestinal cytoprotective effect.



European Patent
Office

EUROPEAN SEARCH REPORT

0171372

Application number

EP 85850199.2

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
	No documents have been disclosed.		C07D 513/14 A61K 31/54
			TECHNICAL FIELDS SEARCHED (Int. Cl. 3)
			C07D A61K
The present search report has been drawn up for all claims			
Place of search STOCKHOLM		Date of completion of the search 13-09-1985	Examiner ELFVING L.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			